The Myelodysplastic Syndromes Foundation
The MDS foundation is a global nonprofit dedicated to improving the lives of patients with myelodysplastic syndromes (MDS) through patient support, education, advocacy, research, and collaboration to advance better care and outcomes worldwide.
The Myelodysplastic Syndromes Foundation at a glance
- Total assets
- $2,623,801
- -31.8% vs 2024
- Revenue (2025)
- $1,859,509
- -7.1% vs 2024
- Net investment income (2025)
- $27,075
- +659.9% vs 2024
- Expenses (2025)
- $3,034,024
- +2.7% vs 2024
- Latest 990 filing
- Form 990, 2025 View filing
Data from IRS Form 990, 2025; updated September 2026.
Who The Myelodysplastic Syndromes Foundation funds
How this funder distributes its grants
Grant Size Distribution
6 grants across all recorded years
The most common grant size was under $50K: 3 grants of 6 (50%).
Geographic Focus
Where this funder awards grants
Grant Distribution by State
Cities
How The Myelodysplastic Syndromes Foundation gives
- Giving held roughly steady from 2020 to 2023 (−20%). Method
From the foundation's IRS Form 990 filings. Methodology.
Giving History
Giving Over Time
Total grant dollars and number of grants per year
From 2020 to 2023, annual grant giving ranged from $165K (2021) to $295K (2020). In 2023 it made 3 grants totaling $237K.
Hatched bars: grants paid as reported on the IRS filing, which lists no individual grants for that year.
Grants by year
Grant recipients and amounts by year
| Recipient | Purpose | Amount |
|---|---|---|
| H Lee Moffitt Cancer Center & Research La Jolla, CA | IWG Sequencing | $116,819 |
| Washington University in St Louis St. Louis, MO | Research | $100,000 |
| Ucsd San Diego Moores Cancer Center San Diego, CA | Support | $19,954 |
Ready to take the next step with The Myelodysplastic Syndromes Foundation?
Financial History
Multi-year comparison from IRS filings
| Filing year | Total Assets | Revenue | Expenses | Grants paid | Grants | Net Investment Income |
|---|---|---|---|---|---|---|
| 2025 | $2,623,801 | $1,859,509 | $3,034,024 | — | — | $27,075 |
| 2024 | $3,847,112 | $2,002,126 | $2,953,868 | — | — | $3,563 |
| 2023 | $5,146,339 | $2,562,806 | $3,312,848 | $236,773 | 3 | $32,321 |
| 2022 | $5,422,226 | $2,521,375 | $2,174,159 | $240,484 | Total only | $8,487 |
| 2021 | $5,238,327 | $4,660,616 | $2,815,786 | $165,404 | 3 | $2,252 |
| 2020 | $3,276,887 | $3,289,167 | $2,011,416 | $294,550 | 2 | $2,543 |
"Total only": grants paid as reported on the IRS filing, which lists no individual grants for that year.
About The Myelodysplastic Syndromes Foundation
Based on IRS filings
The Myelodysplastic Syndromes Foundation is a public charity focused on Diseases, Disorders & Medical Disciplines, based in New York, NY. IRS filing data is available from 2020 through 2025. As of 2025, the organization holds $2.6M in total assets. Net investment income was $27K.
Focus Areas
Leadership & Key People
Officers and directors from IRS filings
The Myelodysplastic Syndromes Foundation is led by Peggy Ann Torney, CEO on the 2025 filing; 4 of 11 officers listed in 2025 are compensated.
Officers on the 2025 filing
Peggy Ann Torney
CEO
New on the 2025 filing
40 hrs/week
$228K (2025)
Stephen D. Nimer MD
Chairman
Chariman → Chairman, 2022
On filings since 2020
3 hrs/week
No compensation reported
Ashley R. Moncrief
Patient Care Director
On filings since 2024
40 hrs/week
$137K (2024) → $144K (2025)
Tanya Rhodes
Development Director
On filings since 2024
40 hrs/week
$124K (2024) → $113K (2025)
Luca Malcovati
Director
Board Member → Director, 2024
On filings since 2020
1 hr/week
No compensation reported
Michael R. Savona MD
Director
Board Member → Director, 2024
On filings since 2020
1 hr/week
No compensation reported
Peter L. Greenberg MD
Director
Board Member → Director, 2024
On filings since 2020
1 hr/week
No compensation reported
Pierre Fenaux
Director
Board Member → Director, 2024
On filings since 2020
1 hr/week
No compensation reported
Jim Williams
Director
New on the 2025 filing
1 hr/week
No compensation reported
Lea Harrison
Secretary
On filings since 2024
40 hrs/week
$93K (2024) → $105K (2025)
Sandy Kurtin
Treasurer
On filings since 2024
4 hrs/week
No compensation reported
Former officers (3)
- Former: Tracey A. Iraca (2020–2024) — Executive Director
- Former: Janice Butchko (2020–2023) — Secretary
- Former: Sandra Kurtin Phd Anp-C Aocn (2020–2023) — Treasurer
Data from IRS Form 990 filings, 2020–2025. "On filings since" is the earliest filing we hold that lists the person; hours are average hours per week as reported.
Compensation Overview
From 2025 IRS filing
The highest reported compensation on the 2025 filing was $228K, to Peggy Ann Torney (CEO). 4 officers or directors reported compensation on that filing.
Frequently asked questions about The Myelodysplastic Syndromes Foundation
How large is The Myelodysplastic Syndromes Foundation?
The Myelodysplastic Syndromes Foundation reported $2.6M in total assets on its 2025 IRS Form 990. Its revenue that year was $1.9M.
What is The Myelodysplastic Syndromes Foundation?
The Myelodysplastic Syndromes Foundation is a public charity focused on Diseases, Disorders & Medical Disciplines, based in New York, NY. It holds $2.6M in total assets as of 2025.
Where does The Myelodysplastic Syndromes Foundation operate?
The Myelodysplastic Syndromes Foundation has awarded grants in California, Florida, Massachusetts, Missouri, New Jersey, New York.
What is The Myelodysplastic Syndromes Foundation's EIN?
The Myelodysplastic Syndromes Foundation's EIN (Employer Identification Number) is 22-3283911. IRS Form 990 filing data is available on this page for 2020–2025.
Data last updated September 2026. Sourced from IRS Form 990 filings.
Data update history
(6)
When this profile's IRS filing data changed on Grantable
- Updated Form 990 for fiscal year 2020 (received by the IRS August 26, 2021)
- Updated Form 990 for fiscal year 2021 (received by the IRS June 9, 2023)
- Updated Form 990 for fiscal year 2023 (received by the IRS October 24, 2025)
- Updated Form 990 for fiscal year 2022 (received by the IRS November 14, 2023)
- Added Form 990 for fiscal year 2025 (received by the IRS August 26, 2026)
- IRS filings on file for fiscal years 2020–2024
Live grants for the work The Myelodysplastic Syndromes Foundation funds
Diseases, Disorders & Medical Disciplines Open opportunities, soonest deadline first.
Explore Open Grants
Browse active grant opportunities in The Myelodysplastic Syndromes Foundation's focus areas in our free grants database
Similar Funders
Funders with grantees in common
The Ovarian Cancer Research Fund Inc
New York, NY
Ovarian Cancer Research Alliance funds research on ovarian and related gynecologic cancers, including early detection, treatment, recurrence, and health equity, through grants to eligible nonprofit research institutions. Its 2024 grants ranged from $75,000 to $900,000, with a median of about $325,000; LOIs are open to researchers worldwide, though funding is limited to specified nonprofit institutions. It accepts requests through grant programs with an LOI and peer-review process, with full proposals by invitation.
Assets
$42.6M
Grants
18
Total Given
$7.9M
Conquer Cancer Foundation of the American Society of Clinical Oncology
Alexandria, VA
Conquer Cancer funds cancer research, professional education, and quality-care initiatives, with awards to universities, hospitals, and cancer centers in the U.S. and through international programs. Its 2024 grants ranged from $50,000 to $7.68 million, with a median of $100,000; the profile does not state whether it accepts unsolicited requests.
Assets
$120.7M
Grants
39
Total Given
$17.4M
Edward P Evans Foundation
Charlestown, MA
The Edward P. Evans Foundation primarily funds collaborative medical research on MDS and AML, with additional support for educational-institution capital projects and modern American visual arts. Its 2025 grants ranged from $25,000 to $1,602,500, with a median of $200,000, and went to organizations in multiple states. It does not accept unsolicited requests and gives only to preselected charitable organizations.
Assets
$260.6M
Grants
44
Total Given
$14.2M
The Mark Foundation for Cancer Research (US) Ltd
New York, NY
The Mark Foundation for Cancer Research funds basic, translational, and clinical cancer research, including collaborative projects and early-stage drug discovery, at institutions in the U.S. and internationally. Its 2024 grants ranged from $11,250 to $2.75 million, with a median of $500,000; ASPIRE individual applications may be considered by invitation, and no general unsolicited-request policy is stated.
Assets
$105.5M
Grants
29
Total Given
$19.5M
Melanoma Research Alliance Foundation
Washington, DC
The Melanoma Research Alliance Foundation funds research to prevent, detect, diagnose, and treat melanoma, along with patient education and engagement, through grants to U.S. and international research organizations. Its 2024 grants had a median of $255,000 and ranged from $12,000 to $1.155 million; the profile does not state whether it accepts unsolicited requests.
Assets
$25.2M
Grants
29
Total Given
$11.9M
The V Foundation
Cary, NC
The V Foundation funds high-risk, high-reward research on all types of cancer through researchers at cancer centers and other exceptional institutions in the United States and selected Canadian centers. Its grants vary by program; 2025 awards ranged from $84,000 to $3.2 million, with a median of $800,000. It does not accept unsolicited requests; selected institutions are invited to apply.
Assets
$145.9M
Grants
53
Total Given
$56.7M
More similar funders
More Funders in New York
The filing figures on this page are open data under CC BY 4.0. About GrantGraph Open
Figures come from The Myelodysplastic Syndromes Foundation's IRS filings (methodology). AI-written summaries, news items and logos are not covered by the open licence. Spot an error? Email hello@grantable.co.
The Myelodysplastic Syndromes Foundation down — hundreds of funders to go?